Are Non-Psychoactive Cannabis Cannabinoids Better for Elderly with Dementia?

PostedMarch 11, 2026

UpdatedMarch 11, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As medical cannabis becomes more widely discussed as a treatment for various conditions, non-psychoactive cannabinoids, particularly CBD (cannabidiol), have gained attention for their potential benefits in elderly patients with dementia. Unlike THC (tetrahydrocannabinol), which can cause psychoactive effects and may worsen symptoms like confusion and agitation, CBD is non-psychoactive and is believed to offer a safer alternative.

What The Research Shows

Several studies have suggested that CBD may help reduce anxiety, agitation, and improve sleep in dementia patients without causing confusion or hallucinations that are sometimes associated with THC.

A 2021 study published in Frontiers in Pharmacology reviewed the effects of CBD on neurodegenerative diseases, including dementia, and found that CBD had a positive impact on behaviour and mood without causing significant side effects. Additionally, a 2020 study in Frontiers in Neurology indicated that CBD-rich cannabis extracts could significantly reduce agitation and anxiety in patients with Alzheimer’s disease, showing promise for managing behavioural symptoms.

What The Guidelines Say

In their NG144 guidelines, NICE highlights the lack of robust evidence supporting the use of cannabis products for dementia, emphasising that clinical trials are essential to determine both efficacy and safety. The NHS also does not approve the use of CBD or cannabis-based products for treating dementia in the UK, noting that they are only licensed for certain conditions like epilepsy or multiple sclerosis.

Expert Commentary

The Alzheimer’s Society acknowledges that while CBD may offer some benefits, particularly for agitation and anxiety, it is not yet a proven treatment for dementia symptoms. Experts, including those at the Royal College of Psychiatrists, recommend that any use of cannabinoid-based treatments be closely monitored and confined to regulated clinical research.

Clinical Bottom Line

Non-psychoactive CBD may offer a safer alternative to THC for elderly patients with dementia, reducing agitation and improving sleep.

Evidence for CBD’s efficacy is still limited, with many studies being small-scale or lacking robust long-term data.

NICE and NHS guidelines advise against using CBD for dementia outside of clinical trials.

Standardised dosages and formulations of CBD are needed for better comparison across studies.

Future research may clarify whether CBD can be a useful tool for managing dementia-related sleep issues and agitation.

About AlleviMed

If you are considering whether medical cannabis could be appropriate for a loved one with dementia, AlleviMed offers private eligibility consultations across the UK. The service connects families with GMC-registered specialists for safe, compliant advice on evidence-based cannabis treatments. You can learn more at allevimed.co.uk once the site is live.

Takeaway

CBD shows potential for reducing agitation and improving sleep in dementia patients, though evidence remains inconclusive. While CBD may offer a safer alternative to THC, NICE and NHS guidelines currently recommend its use only in clinical trials. Further large-scale studies are needed to assess its safety and long-term effectiveness in managing dementia symptoms.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.